AIM ImmunoTech 2026年季度报告

FORM 10-Q ☒Quarterly Report Pursuant to Section 13 or 15(d)of the Securities Exchange Act of 1934 ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THESECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2026 Commission File Number: 001-27072 Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Actof 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has beensubject to such filing requirements for the past 90 days.☒Yes☐No Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or such shorter period that the registrant was required tosubmit and post such files).☒Yes☐No Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reportingcompany or an emerging growth company. See definition of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and“emerging growth company” in Rule 12b-2 of the Exchange Act. ☐Accelerated filer☒Smaller reporting company☐Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complyingwith any new or revised financial accounting standards pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).☐Yes☒No 30,442,139 shares of common stock were outstanding as of August 7, 2026. AIM IMMUNOTECH INC. AND SUBSIDIARIESCondensed Consolidated Balance Sheets(in thousands, except for share and per share amounts)(Unaudited June 30, 2026 and Audited December 31, 2025) AIM IMMUNOTECH INC. AND SUBSIDIARIESNOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Note 1: Business and Basis of Presentation AIM ImmunoTech Inc. and its subsidiaries are an immuno-pharma company headquartered in Ocala, Florida, with a strong foundation oflaboratory, pre-clinical and clinical data with respect to the development of nucleic acids and natural interferon to enhance the natural antiviraldefense system of the human body. AIM’s products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is adouble-stranded RNA (“dsRNA”) molecule being developed for the treatment of late-stage pancreatic cancer, in addition to other globallyimportant cancers, viral diseases and disorders of the immune system. Ampligen has not been approved by the FDA or marketed in the UnitedStates, but it is approved for commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (“CFS”). The Company’s research and development of Ampligen includes a variety of diseases and health matters: ●Conducting clinical trials to evaluate the efficacy and safety of Ampligen for the treatment of pancreatic cancer.●Evaluating Ampligen across multiple cancers as a potential therapy that modifies the tumor microenvironment with the goal ofincreasing anti-tumor responses to checkpoint inhibitors.●Exploring Ampligen’s antiviral activities and potential use as a prophylactic or treatment for existing viruses, new viruses and mutatedviruses thereof.●Evaluating Ampligen as a treatment for myalgic encephalomyelitis/chronic fatigue syndrome (“ME/CFS”) and fatigue and/or the Post-COVID condition of fatigue.●Evaluating Ampligen as a vaccine adjuvant in the combination of Ampligen and AstraZeneca’s FluMist as an intranasal vaccine forinfluenza, including avian influenza. Ampligen is a wide-spectrum therapeutic that has shown positive safety and efficacy in clinical trials of several different solid tumor types.Based specifically on clinical success as to safety and efficacy in our pancreatic cancer Early Access Program and an ongoing Phase 2 trial,AIM has made the business decision to focus its efforts on the development of Ampligen for the treatment of late-stage pancreatic cancer, as webelieve that this path will potentially lead to the most lucrative outcome. Pancreatic cancer is expected to kill an estimated 100,000 people inthe American and European Union markets — and more than 450,000 people worldwide in 2026. When AIM looks at the global healthproblem of pancreatic cancer, we see a large market for an unmet medical need and with relatively little clinical competition. We believe we arewell positioned to serve this market with our intellectual property program which includes broad-combination therapy patents in the UnitedStates, Japan and Europe, as well as market exclusivity provided by orphan drug designations in the United States and the European Union. Oncology is an area of biotech which can generate multibillion-dollar me